What Is a Normal Cholesterol Level in Menopause?

What Is a Normal Cholesterol Level in Menopause?

For most women in menopause, a total cholesterol below 200 mg/dL is still the general target, but that single number tells only part of the story. Estrogen loss causes LDL to rise, HDL to drift lower, and triglycerides to climb — so your ratio and particle breakdown matter more than total cholesterol alone. The exception: women who enter menopause with already-elevated LDL or a family history of cardiovascular disease need tighter targets and earlier intervention.

---

Why Estrogen Loss Changes Your Cholesterol Profile

Estrogen is a powerful regulator of lipid metabolism. It upregulates LDL receptors in the liver, which keeps circulating LDL low, and it supports HDL synthesis. When estrogen drops at menopause — typically declining sharply in the two to three years surrounding the final menstrual period — both of those effects are lost simultaneously.

Data from the Study of Women's Health Across the Nation (SWAN) found that LDL cholesterol increased by an average of 9–14 mg/dL in the menopausal transition, with the steepest rise occurring in the two years before and after the final period (Matthews et al., Archives of Internal Medicine 2009; PMID: 19901134). HDL dropped modestly, and triglycerides tended to rise, particularly in women who also gained visceral fat.

The mechanism behind this LDL rise is worth understanding in detail. Estradiol increases the expression of hepatic LDL receptors (LDLRs) by suppressing PCSK9 — the same protein that pharmaceutical PCSK9 inhibitors target. When estradiol falls, PCSK9 activity rises, LDLR expression decreases, and LDL particles remain in circulation longer before clearance. This is why the LDL rise at menopause closely mirrors what happens when someone is given a PCSK9 activator pharmacologically: it is a receptor-density problem, not simply a production problem. Separately, estrogen promotes lipoprotein lipase activity, which clears triglyceride-rich VLDL from the bloodstream. Loss of this effect explains the concurrent rise in triglycerides many women see at the same time as the LDL increase.

This shift is not cosmetic. Cardiovascular disease becomes the leading cause of death in women after menopause, and the lipid changes described above are a meaningful part of why. A 10 mg/dL sustained increase in LDL is associated with roughly a 20% increase in major cardiovascular events over a decade, according to Mendelian randomization data (Ference et al., JAMA 2017; PMID: 28654651).

Understanding what causes total cholesterol to be out of range gives important context here — some of what drives cholesterol up in midlife is hormonal, and some of it is dietary, metabolic, and genetic, all acting at once.

---

Optimal vs. Reference Ranges: Reading Your Lab Report

Clinical labs typically report reference ranges based on population averages, which often include women who are already metabolically compromised. Optimal ranges are more useful targets:

For a deeper look at how the ratio calculation works and what moves it, see what causes cholesterol ratio to be out of range.

The non-HDL cholesterol figure — total minus HDL — is increasingly preferred by cardiologists because it captures all atherogenic particles including VLDL, IDL, and remnant cholesterol, not just LDL. For postmenopausal women, non-HDL is often a more accurate predictor of risk than LDL alone (Ridker et al., JAMA 2005; PMID: 15755944).

One marker not on every standard lipid panel but worth requesting is ApoB (apolipoprotein B). Each atherogenic particle carries exactly one ApoB molecule, so it directly counts particle number rather than estimating mass. This matters clinically because two women can have identical LDL-C values yet carry very different numbers of LDL particles — the woman with more, smaller particles carries more ApoB and more atherogenic risk even though the reported cholesterol mass looks equivalent. For more on how this marker is interpreted, see understanding what causes ApoB to be out of range.

---

How Perimenopause Differs From Post-Menopause Cholesterol Risk

The transition — perimenopause — is when the most volatile changes happen. Estrogen levels fluctuate erratically before they fall for good, and these fluctuations can cause lipid levels to swing between labs. A cholesterol test during a high-estrogen phase in perimenopause may look fine; one taken three months later during a low-estrogen phase may look alarming.

If you are in perimenopause and your cholesterol has just started creeping up, it is worth asking your provider for a full fasting lipid panel rather than a non-fasting one, and repeating it at a different phase of your cycle (if you still have one) before drawing conclusions. The article on what is a normal cholesterol level in perimenopause covers these fluctuations in more detail.

Once menopause is confirmed (12 consecutive months without a period), LDL tends to plateau at a new, higher setpoint. This is the level that should be compared against the optimal ranges in the table above and treated accordingly. Importantly, some research suggests that the timing of lipid intervention relative to the menopause transition matters: women who addressed rising LDL in early postmenopause had better long-term cardiovascular outcomes than those who waited until LDL was already substantially elevated — a concept analogous to the "timing hypothesis" more commonly discussed in the context of hormone therapy (Hodis & Mack, Journal of Clinical Endocrinology & Metabolism 2022; PMID: 35438139).

Women who also have insulin resistance or polycystic ovary syndrome (PCOS) may enter perimenopause with already-unfavorable lipid profiles that worsen further with the estrogen withdrawal. If that describes you, the context around what is a normal cholesterol level in PCOS is worth reading before your next lipid panel.

---

Diet, Lifestyle, and Supplement Strategies That Actually Move the Numbers

Pharmacological intervention (statins, ezetimibe, PCSK9 inhibitors) is appropriate for high-risk women, but the majority of perimenopausal and postmenopausal women are in an intermediate-risk zone where diet and targeted supplementation can meaningfully change trajectory before a prescription is necessary.

Dietary Interventions With Evidence

Soluble fiber is one of the most consistently effective non-drug interventions for LDL. A meta-analysis of 67 controlled trials found that each additional 2–10 grams of soluble fiber per day reduced LDL by 1.7 mg/dL on average, with greater effects in people with higher baseline levels (Brown et al., American Journal of Clinical Nutrition 1999; PMID: 9925120). Oats, psyllium, lentils, and flaxseed are high-yield sources. At the upper end — 10–12 g/day of psyllium husk specifically — LDL reductions of 6–7% have been reported in trials of hypercholesterolemic adults, which is a clinically meaningful shift for someone at the borderline threshold.

Replacing saturated fat with unsaturated fat remains foundational. The Mediterranean dietary pattern — high in olive oil, fatty fish, legumes, and vegetables — has been shown to reduce cardiovascular events in high-risk populations and is associated with more favorable lipid profiles in postmenopausal women specifically. A key mechanism is that oleic acid (the primary fatty acid in olive oil) does not upregulate PCSK9 the way palmitic acid (the primary saturated fat in red meat and dairy) does, making unsaturated fat substitution a partial LDL receptor rescue strategy.

Reducing refined carbohydrates and alcohol is particularly important for triglycerides, which tend to be more diet-responsive than LDL in this population. Fructose is especially potent at driving hepatic triglyceride synthesis; replacing sugar-sweetened beverages with water or unsweetened alternatives is often the single most effective dietary move for triglyceride reduction.

Exercise

Aerobic exercise raises HDL and lowers triglycerides more reliably than it lowers LDL. Resistance training appears to reduce small, dense LDL particles — the most atherogenic subtype — even without large changes in the total LDL number. For postmenopausal women, combining both modalities for at least 150 minutes of moderate-intensity activity per week is the evidence-supported target (American Heart Association position statement). High-intensity interval training (HIIT) appears to raise HDL more efficiently per minute of exercise than steady-state cardio in midlife women, making it a time-efficient option for those with constrained schedules.

Stress and Cortisol: An Underappreciated Driver

Chronic stress elevates cortisol, which increases hepatic cholesterol synthesis and promotes insulin resistance — both of which push LDL and triglycerides higher. Many women notice their cholesterol creeps up during prolonged high-stress periods, which makes sense biochemically: cortisol upregulates HMG-CoA reductase, the same enzyme statins block. In one controlled study, acute psychological stress induced measurable increases in total cholesterol and LDL within 30–60 minutes, suggesting that even the stress of a blood draw can transiently inflate results if a person is acutely anxious at the time of testing (Steptoe et al., Health Psychology 2005; PMID: 16045378).

For women navigating the psychological weight of the menopausal transition — the mood disruption, the identity shifts, the feeling of losing a former version of oneself — it is important to recognize that the emotional burden is not separate from the cardiovascular burden. They share a cortisol-mediated pathway. Practices with measurable cortisol-lowering evidence include regular aerobic exercise, mindfulness-based stress reduction (MBSR), and adaptogenic support where indicated.

---

What This Means for Your Formula

When Ones reviews a user's lab results, the AI looks at the full lipid picture — LDL, HDL, triglycerides, non-HDL, and ApoB if available — alongside inflammatory markers, fasting insulin, and metabolic data from wearables. Three ingredients in the Ones catalog are particularly relevant for women navigating cholesterol changes in menopause:

Omega-3 (EPA/DHA): At doses of 2–4 g/day of combined EPA and DHA, fish oil consistently reduces triglycerides by 20–30% in clinical trials, with the most robust effects in people with triglycerides above 150 mg/dL (Miller et al., Journal of the American Dietetic Association 2009). The FDA has approved icosapentaenoic acid (EPA) at 4 g/day specifically for severe hypertriglyceridemia, and the REDUCE-IT trial demonstrated a 25% reduction in major cardiovascular events in patients on high-dose EPA despite already being on statins — underscoring that the benefit extends beyond simple triglyceride lowering. Ones sources pharmaceutical-grade EPA/DHA calibrated to the user's triglyceride level and capsule budget.

Berberine: This plant alkaloid activates AMPK and upregulates LDL receptors through a pathway that partially overlaps with statins but is mechanistically distinct — it works by inhibiting furin, the convertase that processes PCSK9, rather than blocking HMG-CoA reductase. A 2004 randomized controlled trial in patients with elevated LDL found berberine at 500 mg twice daily reduced LDL by 25% and triglycerides by 35% over 3 months (Kong et al., Journal of Cardiovascular Pharmacology 2004; PMID: 15220420). For women who are not yet at the threshold for statin therapy, berberine can meaningfully shift the lipid profile. Note that berberine should not be combined with statins without medical supervision, as both pathways act on hepatic cholesterol clearance.

Ones Heart Support blend: This proprietary combination targets multiple aspects of cardiovascular metabolism including CoQ10, which supports mitochondrial energy in cardiac tissue and is particularly relevant for women on statins (statins deplete endogenous CoQ10 by inhibiting the same mevalonate pathway used to synthesize it). CoQ10 at 200 mg in the ubiquinol form — the reduced, directly usable form — is the dose used in published trials and is what Ones includes where clinically indicated.

If your HDL is below the optimal threshold, it is worth understanding what is an optimal HDL cholesterol level and which specific interventions target HDL rather than LDL.

---

When to Talk to Your Doctor About Medication

Supplements and lifestyle change are appropriate first-line strategies for women with borderline-elevated cholesterol and no other major risk factors. However, medication is clearly appropriate when:

• LDL is persistently above 160 mg/dL despite 3–6 months of dietary change
• You have a 10-year cardiovascular risk above 7.5% (calculated by your provider using the Pooled Cohort Equations)
• You have a confirmed family history of premature cardiovascular disease or familial hypercholesterolemia
• You have already had a cardiovascular event (in which case LDL target is typically < 70 mg/dL)

For women with borderline risk scores (5–7.5% 10-year risk), coronary artery calcium (CAC) scoring is increasingly used as a tie-breaker: a CAC score of zero in this group supports deferring medication, while any detectable calcification generally tips the balance toward initiating a statin. This nuance is worth discussing explicitly with your cardiologist rather than relying solely on the cholesterol numbers in isolation.

This is not a decision to make based on a single lab result or a supplement protocol. It requires a conversation with a physician or cardiologist who can assess your full risk picture.

---

Key Takeaways

• Total cholesterol below 200 mg/dL remains the general target, but LDL, non-HDL, ApoB, and the total:HDL ratio are more informative markers in menopausal women.
• Estrogen withdrawal drives LDL higher by suppressing LDLR expression via PCSK9 upregulation — it is a receptor-density problem, not just overproduction, and the sharpest changes occur in the two to three years surrounding the final period.
• The cholesterol number on your lab report is a reference range, not an optimal range. Optimal LDL for cardiovascular longevity is below 100 mg/dL for most women and below 70 mg/dL for higher-risk individuals.
• Soluble fiber, aerobic exercise, omega-3 fatty acids, and cortisol management are the lifestyle interventions with the strongest evidence for improving the lipid profile without medication.
• Berberine (500 mg twice daily) and omega-3 supplementation (2–4 g EPA/DHA) can meaningfully shift LDL and triglycerides respectively, but doses need to match clinical trial levels to produce clinical trial effects.
• Medication is indicated for high-risk women or those who do not respond to lifestyle change — consult a healthcare provider to calculate your 10-year cardiovascular risk and consider CAC scoring if your risk is borderline.